Adding Phosphorus to Osteoporosis Drug Treatment
Drug: Calcium carbonate
Drug: Calcium phosphate
Drug: Vitamin D
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Bone Sparing by Calcium Salts With and Without Extra Phosphorus|
- Change in lumbar spine and hip BMD [ Time Frame: Measured at 12 months ] [ Designated as safety issue: No ]
- Change in remodeling biomarkers [ Time Frame: Measured at 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||August 2004|
|Study Completion Date:||June 2008|
|Primary Completion Date:||June 2008 (Final data collection date for primary outcome measure)|
Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
|Drug: Calcium phosphate Drug: Teriparatide Drug: Vitamin D|
Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
|Drug: Calcium carbonate Drug: Teriparatide Drug: Vitamin D|
Osteoporosis is the most common type of bone disease. Calcium supplements normally used in anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts bind phosphorus from food in the intestine and restrict phosphorus available for bone building. This study will evaluate the efficacy of adding calcium phosphate to a regimen of teriparatide and vitamin D in increasing bone mineral density in women with osteoporosis. It is hypothesized that the group taking the phosphate-containing calcium supplement will have greater gains in bone mineral density (BMD) during the course of the study than the group not receiving phosphate.
All participants will receive teriparatide and vitamin D during the course of the 12-month study. Participants will be randomly assigned to one of two groups. One group will receive calcium phosphate and the other will receive calcium carbonate. BMD will be measured at spine and hip at baseline and at 3, 6, and 12 months of treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00074711
|United States, Nebraska|
|Creighton University Medical Center|
|Omaha, Nebraska, United States, 68131|
|Principal Investigator:||Robert P. Heaney, MD||Creighton University Medical Center|